

March 12, 2021



Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology

Technology invented and developed at Cleveland Clinic

SAN JOSE, Calif., March 12, 2021 /PRNewswire/ --[Anixa Biosciences, Inc.](#) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.

The patent is titled, "Ovarian Cancer Vaccines," and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic.

Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, "We are pleased that the European Patent Office (EPO) has issued this patent. This ovarian cancer vaccine has the potential to eliminate one of the deadliest malignancies in women. Ovarian cancer is often diagnosed after it has reached Stage 3 or 4, and when it is difficult to effectively treat. Five-year survival statistics for ovarian cancer are poor, so if this vaccine is able to eliminate the onset of ovarian cancer, the impact for women and for our healthcare system will be tremendous."

"The ovarian cancer vaccine targets a protein (the Extracellular Domain of the Anti-Mullerian Hormone Receptor 2, AMHR2-ED) that is expressed only in the ovaries and only in pre-menopausal women. After menopause, the target protein disappears and is only seen again when ovarian cancer cells arise. Our vaccine targets the AMHR2-ED and trains the immune system to destroy these cancer cells as they arise," said Dr. Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "We are looking forward to our continued alliance with Anixa Biosciences to further develop this technology."

About Anixa Biosciences, Inc.

Anixa is a publicly-traded biotechnology company developing a number of programs

addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Investor contact:

Mike Catelani

mcatelani@anixa.com

408-708-9808

Media contact:

Sherry Ash

anixapress@gmail.com

 View original content to download multimedia <http://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology-301246332.html>

SOURCE Anixa Biosciences, Inc.